Last fall, FDA safety officers began compiling a list of children possibly killed by COVID vaccines. Digging through ...

The INTerpath-001 trial randomized 1,137 patients with resected stage IIB to IV melanoma to Keytruda alone or Keytruda plus ...

A combination of the personalized cancer vaccine intismeran autogene and Merck's Keytruda just barely cleared analysts’ ...

A Moderna and Merck personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% ...

Biotech stocks are rallying as clinical wins, M&A and new drug technologies revive the sector. Here are the ETFs and stocks analysts favor.

The skin cancer vaccine is based on mRNA technology that helped end the coronavirus pandemic.

When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage ...

Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal something retirees cannot afford to ignore. Before ...

Moderna's mFLUSIVA became the first FDA-approved mRNA flu vaccine for adults 50+, but its stock surge stems from cancer ...

Moderna is rated a Hold, citing valuation concerns, lack of definitive long-term efficacy data, and significant execution and ...

Pfizer (NYSE:PFE) signed a new research collaboration and license agreement with Enodia Therapeutics to develop Sec61 ...